6533b7d4fe1ef96bd1261f4a
RESEARCH PRODUCT
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.
Jelena VekicAleksandra ZeljkovicKhalid Al RasadiMustafa CesurJosé Silva-nunesAnca Pantea StoianManfredi Rizzosubject
LipoproteinsEndocrinology Diabetes and MetabolismDiabetes030209 endocrinology & metabolism030204 cardiovascular system & hematologyCardiovascular riskAtherosclerosisIncretinsBiochemistrySmall dense LDL3. Good health03 medical and health sciences0302 clinical medicineAtherosclerosis Cardiovascular risk Diabetes GLP-1 Incretins Lipoproteins Small dense LDL Therapylipids (amino acids peptides and proteins)TherapyGLP-1Molecular Biologydescription
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-01-01 | Metabolites |